Beyond Steroids: Topical Dermatological Efficacy and Patient-Centric Perspectives | videos

Lisa Swanson, MD, FAAD, sheds light on the enhanced accessibility of ruxolitinib cream, highlighting its improved availability for patients in need.

Brad Glick, DO, MPH, FAAD, notes the absence of location restrictions with topical ruxolitinib cream, distinguishing it from topical corticosteroids. The panel discusses the cyclic pattern of steroid use and the potential of ruxolitinib cream as a continuous treatment option.

Dermatology experts evaluate topical ruxolitinib cream's effectiveness in rapidly relieving itch and offer guidance on its black box warning. They also discuss its efficacy in children under 2, highlighting its suitability for those with tactile sensitivity.

Dr James Del Rosso underscores the importance of phase 2 and dose-ranging studies to uncover efficacy differences between therapies, while the panel explores how clinical data from ruxolitinib trials mirrors real-world outcomes.

James Del Rosso, DO, Brad Glick, DO, MPH, FAAD, and Lisa Swanson, MD, FAAD, address the demand for non-steroidal treatment alternatives while navigating the individualization of data interpretation regarding these treatments.

Dr Linda Stein Gold and Dr Michael Cameron assess the safety and tolerability of topical ruxolitinib cream, offering guidance on counseling patients about the black box warning. They also address the perception of limited treatment access and strategies for overcoming this barrier.

Experts in dermatology review the rapid itch relief provided by topical ruxolitinib cream and attribute its fast-acting efficacy to its mechanism of action targeting a variety of interleukins.

Linda Stein Gold, MD, and Michael Cameron, MD, FAAD, discuss the need for non-steroidal treatment options in atopic dermatitis management, driven by patient preferences. They highlight the challenges with previous oily options, which often caused tolerability and irritation issues, and how the approval of ruxolitinib cream addresses these concerns.